

- Bozzetti F., Bertario L., Rossetti C., Gennari L., Andreola S., Baratti D., **Gronchi A.** Surgical treatment of locally recurrent rectal carcinoma. *Disease of the Colon Rectum* 1997; 40 (12): 1421-1424.
- Bozzetti F., Baratti D., Andreola S., Zucali R., Schiavo M., Spinelli P., **Gronchi A.**, Valvo F., Mariani L., Gennari L. Preoperative Radiation Therapy for T2-T3 cancers of the middle-to-lower rectum. *Cancer* 1999; 86 (3): 398-404.
- Azzarelli A., **Gronchi A.**, Bertulli R., Tesoro Tess J.D., Baratti D., Pennacchioli E., Dileo P., Rasponi A., Pilotti S., Casali P.G. Low-dose chemotherapy with Methotrexate and Vinblastine for advanced aggressive fibromatosis. *Cancer* 2001, 92 (5): 1259-1264.
- Mezzelani A., Mariani L., Tamborini E., Agus V., Riva C., Lo Vullo S., Fabbri A., Stumbo M., Azzarelli A., Casali P.G., **Gronchi A.**, Sozzi G., Pierotti M.A., Pilotti S. SYT-SSX fusion genes and prognosis in synovial sarcoma. *Br J of Cancer* 2001, 85 (10): 1535-9.
- Ferrari A., Casanova M., Bisogno G., Mattke A., Meazza C., **Gronchi A.**, Cecchetto G., Fidani P., Kunz D., Treuner J., Carli M. Hemangiopericytoma in pediatric age: a report from the italian and german soft tissue sarcoma cooperative group. *Cancer* 2001, 92 (10): 2692-2698.
- Tamborini E., Agus V., Perrone F., Papini D., Romanò R., Pasini B., **Gronchi A.**, Colecchia M., Rosai J., Pierotti M.A., Pilotti S. Lack of SYT-SSX fusion transcripts in malignant peripheral nerve sheath tumors on RT-PCR analysis of 38 archival cases. *Lab Invest.* 2002, 82 (5): 609-618.
- Deraco M, **Gronchi A.**, Mazzaferro V, Inglese MG, Pennacchioli E, Kusamura S, Rizzi M, Anselmi RA Jr, Vaglini M. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei. *Tumori.* 2002, 88(5):370-5.
- **Gronchi A.**, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, Bertulli R, Fiore M, Olmi P, Santinami M, Rosai J. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. *J Clin Oncol.* 2003; 21(7):1390-7.
- Baratti D, **Gronchi A.**, Pennacchioli E, Lozza L, Colecchia M, Fiore M, Santinami M. Chordoma: natural history and results in 28 patients treated at a single institution. *Ann Surg Oncol.* 2003; 10(3):291-6.
- Ferrari A, Dileo P, Casanova M, Bertulli R , Meazza C, Gandola L, Navarria P, Collini P, **Gronchi A.**, Olmi P, Fossati-Bellani F, Casali PG. Rhabdomyosarcoma in adults: a retrospective analysis of 171 patients treated at a single institution. *Cancer* 2003; 98 (3): 571-580.
- Collini P, Mezzelani A, Modena P, Dagrada P, Tamborini E, Luksch R, **Gronchi A.**, Navarria P, Sozzi G, Pilotti S. Evidence of neural differentiation in a case of post-therapy primitive neuroectodermal tumor/Ewing sarcoma of bone. *Am J Surg Pathol* 2003 Aug;27(8):1161-1166.
- Deraco M, Kusamura S, **Gronchi A.** [Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei]. *Tumori.* 2003 89(4 Suppl): 54-5.
- Perrone F, Tabano S, Colombo F, Dagrada G, Birindelli S, **Gronchi A.**, Colecchia M, Pierotti MA and Pilotti S. p15INK4b, p14ARF and p16INK4a inactivation in sporadic and NF1-related Malignant Peripheral Nerve Sheath Tumors. *Clin Cancer Res.* 2003 Sept.; 9(11): 4132-4138.
- Tamborini E, Bonadiman L, Greco A, **Gronchi A.**, Riva C, Bertulli R, Casali PG, Pierotti MA and Pilotti S. Alternative expression of ligand-activated kit and PDGFRbeta tyrosine kinase receptors in synovial sarcoma. *Clin Cancer Res* 2004 Feb; 10(3): 938-943.
- **Gronchi A.**, Diment J, Colecchia M, Fiore M and Santinami M. Atypical pleomorphic epithelioid angiomyolipoma localized to the pelvis: a case report and review of the literature. *Histopathology* 2004 Mar; 44(3): 292-295.
- Rossi CR, Deraco M, De Simone M, Mocellin S, Pilati P, Foletto M, Cavaliere F, Kusamura S, **Gronchi A.**, Lise M. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis. *Cancer* 2004 May 1;100(9):1943-50.
- **Gronchi A.**, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, Colecchia M, Lozza L, Olmi P, Santinami M and Rosai J. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. *Cancer* 2004, 100(11): 2448-2455.
- Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, **Gronchi A.**, Bertulli R, Colecchia M, Casali PG, Pierotti M and Pilotti S. A new mutation in the ATP pocket of Kit receptor is responsible for acquired resistance to Imatinib in a patient with gastrointestinal stromal tumor (GIST). *Gastroenterology* 2004, 127(1):294-9.

- Ferrari A, **Gronchi A**, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, Casali PG. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. *Cancer* 2004, 101(3): 627-634.
- Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, **Gronchi A**, Orlandi R, Ripamonti C, Spreafico C, Alberti D, Bertieri R, Bertulli R, Coco P, Colecchia M, Fumagalli E, Greco A, Grosso F, Negri T, Olmi P, Pierotti MA, Pilotti S. Imatinib mesylate in chordoma. *Cancer* 2004, 101(9):2086-97.
- Kusamura S, Raspagliesi F, Baratti D, **Gronchi A**, Casali P, Deraco M. Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: a feasibility study. *J Chemother.* 2004, 16 Suppl 5:19-22.
- Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, Casali PG and **Gronchi A**. Validation and adaptation of a nomogram for predicting survival of extremity soft tissue sarcoma using a three grade system. *Cancer* 2005, 103(2):402-408.
- **Gronchi A**, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, Bertulli R, Collini P, Lozza L, Olmi P and Rosai J. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: A series of 911 consecutive patients treated at a single institution. *J Clin Oncol* 2005, 23(1):96-104.
- Diment J, Tamborini E, Casali PG, **Gronchi A**, Carney JA and Colecchia M. Carney Triad: case report and molecular analysis of gastric tumor. *Human Path* 2005, 36: 112-116.
- Ferrari A, Casanova M, Collini P, Meazza C, Lukcsh R, Massimino M, Cefalo G, Terenziani M, Spreafico F, Catania S, Gandola L, **Gronchi A**, Mariani L and Fossati-Bellani F. Adult-type soft tissue sarcoma in pediatric age: experience at the Istituto Nazionale Tumori in Milan. *J Clin Oncol.* 2005, 23(18): 4021-4030.
- Blay JY, Bonvalot S, Casali PG, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, **Gronchi A**, Hogendoorn PCW, Joensuu H, Le Cesne A, Joan Mac Clure, Joan Maurel, Nina Nupponen, Isabelle Ray-Coquard, Peter Reichardt, Raf Sciot, Sigrid Stroobants, Martine van Glabbeke, Allan van Oosterom, Georges D Dimetri. A consensus meeting for the management of gastro-intestinal stromal tumors. Report from the ESMO GIST consensus conference of March 20-21st, 2004. *Ann Oncol.* 2005 Apr;16(4):566-78.
- Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, Lagonigro MS, Gabanti E, Caramuta S, Greco A, Torre GD, **Gronchi A**, Pierotti MA, Pilotti S. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. *Cancer.* 2005, 104: 159-169.
- Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, Casali PG and **Gronchi A**. Dermatofibrosarcoma Protuberans treated at a single institution: a surgical disease with a high cure rate. *J Clin Oncol.* 2005; 23:7669-75.
- Casanova M, Ferrari A, Collini P, Bisogno G, Aleggio R, Cecchetto G, **Gronchi A**, Meazza C, Garaventa A, Di Cataldo A, Carli M. Epithelioid Sarcoma in children and adolescents: a report from the Italian soft tissue sarcoma committee. *Cancer.* 2006; 106(3):708-17.
- Fiore M, Casali PG, Miceli R, Mariani L, Bertulli R, Lozza L, Collini P, Olmi P, Mussi C and **Gronchi A**. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremities. *Ann Surg Oncol.* 2006; 13(1):110-7.
- Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S and **Gronchi A**. Malignant peripheral nerve sheath tumours: prognostic factors and survival in a series of patients treated at a single institution. *Cancer.* 2006; 107(5):1065-1074.
- Tamborini E, Prici S, Negri T, Lagonigro MS, Miselli F, Greco A, **Gronchi A**, Casali PG, Ferrone M, Fermeglia M, Carbone A, Pierotti MA, Pilotti S. Functional analyses and molecular modeling of two c-Kit mutations responsible for Imatinib secondary resistance in GIST patients. *Oncogene.* 2006, 25(45): 6140-6146.
- Costa A, Daidone MG, Daprao L, Villa R, Cantù S, Pilotti S, Mariani L, **Gronchi A**, Henson JD, Reddel RR and Zaffaroni N. Telomere maintenance mechanisms in liposarcoma: association with histologic subtypes and disease progression. *Cancer Res.* 2006; 66(17):8918-24.
- Tamborini E, Miselli F, Negri T, Lagonigro S, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, **Gronchi A**, Perrone F, Carbone A, Pierotti MA, Casali PG and Pilotti S. Molecular and biochemical analyses of PDGFRB, PDGFRA and KIT receptors in chordoma. *Clin Cancer Res.* 2006; 12(23):6920-8.
- Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, Olmi P, Casali PG, Santinami M and **Gronchi A**. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. *Ann Surg Oncol* 2007; 14(2): 553-9.
- **Gronchi A**, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S and Casali PG. Surgery of residual disease following molecular targeted therapy with Imatinib mesylate in advanced/metastatic GIST. *Ann Surg* 2007; 245: 341-346.

- Miselli F, Casieri P, Negri T, Orsenigo M, Lagonigro MS, **Gronchi A**, Fiore M, Casali PG, Bertulli R, Carbone A, Pienotti MA, Tamborini E and Pilotti S. c-Kit/PDGFR $\alpha$  gene status alterations possibly related to primary Imatinib resistance in Gastrointestinal Stromal Tumors. *Clin Cancer Res* 2007; 13(8): 2369-77.
- Tamborini E, Casieri P, Miselli F, Orsenigo M, Negri T, Piacenza C, Stacchiotti S, **Gronchi A**, Pastorino U, Pierotti MA and Pilotti S. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. *J Pathol* 2007; 212(2):227-235.
- **Gronchi A**, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, Mariani L and Casali PG. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. *Ann Surg Oncol* 2007; 14(5):1583-90.
- Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, Collini P, Lozza L, Mariani L, Casali PG and **Gronchi A**. Myxoid/round cell and pleomorphic liposarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Cancer* 109: 2522-2531; 2007.
- Casali PG, Stacchiotti S, Sangalli C, Olmi P, **Gronchi A**. Chordoma. *Curr Opin Oncol* 2007; 19(4): 367-370.
- Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero TC, Jimeno J, D'Incalci M, **Gronchi A**, Fletcher JA, Pilotti S, Casali PG. Efficacy of trabectedin (ET-743) in advanced pre- treated myxoid liposarcomas. *Lancet Oncol* 2007; 8(7): 595-602.
- Casanova M, Meazza C, **Gronchi A**, Fiore M, Zaffignani E, Podda M, Collini P, Gandola L, Ferrari A. Soft tissue sarcoma of the extremities in patients of pediatric age. *J Child Orthop* 2007; 1(3):195-203.
- Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, **Gronchi A**, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J; NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. *J Natl Compr Canc Netw*. 2007; 5 Suppl 2:S1-29.
- **Gronchi A**, Olmi P and Casali PG. Combined modalities approach for localized adult extremity soft tissue sarcoma. *Expert Rev. Anticancer Ther* 2007; 7(8): 1135-1144.
- Signoroni S, Frattini M, Negri T, Pastore E, Tamborini E, Casieri P, Orsenigo M, Da Riva L, Radice P, Sala P, **Gronchi A**, Bertario L, Pierotti MA and Pilotti S. Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as potential targets in treating Aggressive Fibromatosis. *Clin Cancer Res* 2007; 13(17): 5034-5040.
- Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, Collini P, Redaelli S, Fiore M and **Gronchi A**. Epithelioid Sarcoma: Prognostic Factors and Survival in a series of Patients Treated at a Single Institution. *Ann Surg Oncol* 2007; 14(12):3542-51.
- Ferrari A, Miceli R, Casanova M, **Gronchi A**, Collini P, Meazza C, Zaffignani E, Massimino M, Spreafico F, Mariani L. Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma. *Eur J Cancer*. 2007 43(18): 2691-2697.
- Venturini L, Erdas R, Costa A, **Gronchi A**, Pilotti S, Zaffaroni N and Daidone MG APB detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcoma. *J Pathol* 2008; 214(4): 410-414.
- Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2008 May;19 Suppl 2:ii35-8.
- Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2008 May;19 Suppl 2:ii89-93.
- Fiore M, Locati P, Mussi C, Guarino A, Piva L, Santinami M and **Gronchi A**. Banked venous homograft replacement of the inferior vena cava for primary leiomyosarcoma. *Eur J Surg Oncol* 2008; 34(6): 720-724.
- Mussi C, Schildhaus HU, **Gronchi A**, Wardelmann E and Hohenberger P. Therapeutic Consequences From Molecular Biology For GIST Patients Affected By Neurofibromatosis Type 1. *Clin Cancer Res* 2008; 14(14): 4550-4555.
- Mussi C, Collini P, Miceli R, Barisella M, Mariani L, Fiore M, Casali PG and **Gronchi A**. Prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of patients surgically treated at a single institution. *Cancer* 2008; 113: 1657-1665.
- Miselli F, Negri T, **Gronchi A**, Losa M, Conca E, Brich S, Fumagalli E, Fiore M, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Is autophagy rather than apoptosis the regression driver in Imatinib-treated gastrointestinal stromal tumours ? *Transl Oncol* 2008; 1(4): 177-186.

- Negri T, Bozzi F, Conca E, Brich S, **Gronchi A**, Bertulli R, Fumagalli E, Pierotti MA, Tamborini E, Pilotti S. Oncogenic and ligand-dependent activation of KIT/PDGFR $\alpha$  in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). *J Pathol* 2009; 217:103-112
- **Gronchi A**, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L and Casali PG. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. *J Clin Oncol* 2009; 27(1): 24-30.
- Ferrari A, Miceli R, Casanova M, Meazza C, Zaffignani E, **Gronchi A**, Piva L, Collini P, Podda M, Massimino M, Luksch R, Cefalo G, Terenziani M, Spreafico F, Polastri D, Mariani L. Soft Tissue Sarcoma of childhood and adolescence: the prognostic role of tumor size changes in relation to the patient's body size. *J Clin Oncol* 2009; 27(3): 371-376..
- Stacchiotti S, Tamborini E, Marrari A, Brich S, Arisi Rota S, Orsenigo M, Crippa F, Morosi C, **Gronchi A**, Pierotti MA, Casali PG and Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma (ASPS). *Clin Cancer Res* 2009, 15(3): 1096-1104
- Pennacchioli E, Fiore M and **Gronchi A**. Hyperthermia as an adjunctive treatment for soft tissue sarcoma. *Expert Rev. Anticancer Ther* 2009, 9(2): 199-210
- Forni C, Minuzzo M, Viridis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, **Gronchi A**, Aman P, Casali PG, D'Incalci M, Pilotti S and Mantovani R. Trabectedin (ET-743) promotes differentiation of myxoid liposarcoma tumors. *Mol Cancer Ther* 2009, 8(2): 449-457
- **Gronchi A**, Bonvalot S, Le Cesne A and Casali PG. Resection of uninvolved adjacent organs can be part of surgery for retroperitoneal soft tissue sarcoma. *J Clin Oncol* 2009, 27(12):2106-2107
- **Gronchi A**, Judson I, Nishida T, Poveda A, Martin J, Reichardt P, Casali PG, Le Cesne A, Hohenberger P, Blay JY. Adjuvant treatment with Imatinib for GIST: solid ground or still quicksand ? A comment on behalf of the EORTC soft tissue and bone sarcoma group, the Italian sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group, the Spanish Sarcoma Group (GEIS). *Eur J Cancer* 2009, 45(7):1103-1106.
- Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V, **Gronchi A** and Casali PG Tumor response assessment in high grade soft tissue sarcomas (STS): a pilot study to assess the correlation between radiological and pathological response using both RECIST and Choi's criteria. *Radiology* 2009, 251(2): 447-456
- Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG and **Gronchi A**. Preoperative Imatinib mesylate for unresectable or locally advanced primary Gastrointestinal Stromal Tumors (GIST). *Eur J Surg Oncol* 2009, 35: 739-745.
- Thomas DM, O'Sullivan B and **Gronchi A**. Current concepts and future perspectives in Retroperitoneal Soft Tissue Sarcoma management. *Expert Rev Anticancer Ther* 2009, 9(8):1145-57
- Reichardt P, Hogendoorn PC, Tamborini E, Loda M, **Gronchi A**, Poveda A, Schöffski P. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. *Semin Oncol*. 2009, 36(4):290-301.
- Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C, Casali PG, Le Cesne A, **Gronchi A** and Bonvalot S. Desmoid-Type Fibromatosis: a front-line conservative approach to select patients for surgical treatment. *Ann Surg Oncol* 2009, 16(9): 2587-2593.
- Grosso F, Sanfilippo R, Viridis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, **Gronchi A**, Pilotti S and Casali PG. Trabectedin in Myxoid Liposarcomas (MLS): a long-term analysis of a single institution series. *Ann Oncol* 2009, 20(8):1439-44
- Colombo C and **Gronchi A**. Desmoid-type fibromatosis: what works best? *Eur J Cancer* 2009, 45 suppl1: 466-467.
- Conca E, Negri T, **Gronchi A**, Fumagalli E, Tamborini E, Pavan GM, Fermeglia M, Pierotti MA, Pricl S and Pilotti S. Activate and Resist: L576P in GIST. *Mol Cancer Ther* 2009, 8(9):2491-2495
- Stacchiotti S, Marrari A, Tamborini E, Palassini E, Viridis E, Messina A, Crippa F, Morosi C, **Gronchi A**, Pilotti S and Casali PG. Response to imatinib plus sirolimus in advanced chordoma. *Ann Oncol* 2009; 20(11):1886-1894.

- Perrone F, Da Riva L, Orsenigo M, Losa M, Jocolle G, Millefanti C, Pastore E, **Gronchi A**, Pierotti MA, and Pilotti S. PDGFRA, PDGFRB, EGFR and downstream signalling activation in malignant peripheral nerve sheath tumour. *Neuro Oncology* 2009; 11(6): 725-736
- Stacchiotti S, Casali PG, Lo Vullo S, Mariani L, Palassini E, Mercuri M, Alberghini M, Pilotti S, Zanella L, **Gronchi A** and Picci P. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centres. *Ann Surg Oncol* 2010; 17: 211-219
- Meazza C, Bisogno G, **Gronchi A**, Fiore M, Cecchetto G, Alaggio R, Milano GM, Casanova M, Carli M, Ferrari A. Aggressive fibromatosis in children and adolescents: the italian experience. *Cancer* 2010; 116(1):233-240
- Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, Fiore M, Hohenberger P and **Gronchi A**. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients ? *Ann Oncol* 2010; 21(2):403-408
- **Gronchi A**, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M and Casali PG. Extremity soft tissue sarcoma in a series of patients treated at a single institution: the local control directly impacts survival. *Ann Surg* 2010; 251: 512-517
- Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, **Gronchi A**, Viridis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M and Allavena P. Anti-tumor and anti-inflammatory effects of Trabectedin on human myxoid liposarcoma cells. *Cancer Res* 2010; 70(6): 2235-2244
- **Gronchi A**, Blay JY and Trent JC. The Role of High-Dose Imatinib in the Management of Patients with Gastrointestinal Stromal Tumor (GIST). *Cancer* 2010; 116(8):1847-1858
- Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, **Gronchi A** and Casali PG. Tumor response to Sunitinib Malate observed in Clear Cell Sarcoma. *Ann Oncol* 2010; 21(5):1130-1131
- Ardoino I., Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, Stacchiotti S, Casali PG and **Gronchi A**. Histology-Specific Nomogram for Primary Retroperitoneal Sarcoma. *Cancer* 2010; 116: 2429-2436
- Stacchiotti S, Negri T, Palassini E, Conca E, **Gronchi A**, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG and Pilotti S. Sunitinib malate and Figitumumab in solitary fibrous tumor (SFT): patterns and molecular bases of tumor response. *Mol Cancer Ther* 2010; 9(5): 1286-1297
- Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, Bouzaiene H, Le Pechouz C, Casali PG, Le Cesne A, Fiore M and **Gronchi A**. Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma carried out at high volume centers is safe and associated to an improved local control. *Ann Surg Oncol* 2010; 17: 1507-1514
- Venturini L, Motta R, **Gronchi A**, Daidone MG and Zaffaroni N. Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. *BMC Cancer* 2010; 10: 254
- Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET. Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010; 21 Suppl 5:v198-203
- Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010; 21 Suppl 5:v98-102.
- Hogendoorn PC; ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiou AH, Whelan J, Vanel D. Bone sarcomas:

ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010; 21 Suppl 5:v204-13.

- Tamborini E, Viridis E, Negri T, Orsenigo M, Brich S, Conca E, **Gronchi A**, Stacchiotti S, Manenti G, Casali PG, Pierotti MA and Pilotti S. Analysis of Receptor Tyrosine Kinases (RTK) and Downstream Pathways in Chordomas. *Neuro Oncol* 2010; 12(8): 776-789
- Frapolli R, Tamborini E, Viridis E, Bello E, Tarantino E, Marchini S, Grosso F, Sanfilippo R, **Gronchi A**, Tercero J, Peloso G, Casali PG, Pilotti S, D'Incalci M. Novel models of Myxoid Liposarcoma Xenografts mimicking the biological and pharmacological features of human tumors. *Clin Cancer Res* 2010;16(20):4958-4967
- Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, Casali PG and **Gronchi A**. Alveolar Soft Part Sarcoma: clinical presentation, treatment and outcome in a series of 33 patients at a single institution. *Ann Surg Oncol* 2010; 17: 3229-3233
- Gatta G, Capocaccia R, Trama A, Martinez-Garzia C; RARECARE Working Group. The burden of rare cancers in Europe. *Adv Exp Med Biol* 2010; 686: 285-303
- Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, **Gronchi A** and Deraco M. Peritoneal Sarcomatosis: is there a subset of patients who may benefit of a cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? *Ann Surg Oncol* 2010; 17(12): 3220-3228
- Orsenigo M, Brich S, Riva C, Conca E, Bertulli R, Dileo P, **Gronchi A**, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Fluorescence in situ hybridization analysis and immunophenotyping of c-kit/PDGFRα and Bcl-2 expression in gastrointestinal stromal tumors. *Anal Quant Cytol Histol* 2010; 32(4): 225-233
- Gennaro M, Valeri B, Casalini P, Carcangiu ML, **Gronchi A**, Conti AR, Agresti R, Greco M. Angiosarcoma of the breast and vascular endothelial growth factor receptor. *Tumori*. 2010; 96(6):930-935.
- Dileo P, Priol S, Tamborini E, Negri T, Stacchiotti S, **Gronchi A**, Posocco P, Laurini E, Coco P, Fumagalli E, Casali PG, Pilotti S. Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRα mutations: an imaging, biochemical and molecular modeling study. *Int J Cancer* 2011; 128(4): 983-990
- Gasparini P, Facchinetti F, Boeri M, Lorenzetto E, Livio A, **Gronchi A**, Ferrari A, Massimino M, Spreafico F, Giangaspero F, Forni M, Maestro R, Alaggio R, Pilotti S, Collini P, Modena P and Sozzi G. Prognostic determinants in Epithelioid Sarcoma. *Eur J Cancer* 2011; 47: 287-295
- Bonvalot S and **Gronchi A**. ILP and RT: the study that will never be. *Ann Surg Oncol* 2011; 18: 303-305
- Sanfilippo R, Miceli R, Grosso F, Fiore M, Pennacchioli E, Puma E, Barisella M, Sangalli C, Mariani L, Casali PG and **Gronchi A**. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Ann Surg Oncol* 2011; 18: 720-725
- Berselli M, Coppola S, Colombo C, Pennacchioli E, Fiore M and **Gronchi A**. Morbidity of Left Pancreatectomy when associated with multivisceral resection for Abdominal Mesenchymal Neoplasm. *JOP* 2011; 12(2): 138-144
- **Gronchi A**, Miceli R, Colombo C, Collini P, Stacchiotti S, Olmi P, Mariani L, Bertulli R, Fiore M and Casali PG. Primary Extremity Soft Tissue Sarcoma: outcome improvement over time at a single institution. *Ann Oncol* 2011; 22(7): 1675-1681
- Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, **Gronchi A**, Casali PG and Pilotti S. Sunitinib in advanced alveolar soft part sarcoma: evidence of direct antitumor effect. *Ann Oncol* 2011; 22(7): 1682-1690
- Bozzi F, Conca E, Manenti G, Negri T, Brich S, **Gronchi A**, Pierotti MA, Tamborini E, Pilotti S. High CD133 expression levels in gastrointestinal stromal tumors. *Cytometry B Clin Cytom* 2011; 80(B): 238-247
- **Gronchi A** and Pollock RE. Surgery in retroperitoneal soft tissue sarcoma: a call for a consensus between Europe and North America. *Ann Surg Oncol* 2011; 18: 2107-2110

- Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, **Gronchi A**, Pilotti S and Casali PG. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. *Int J Cancer* 2011; 129(7): 1761-1772
- Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, **Gronchi A**, Casali PG and Dei Tos AP. Natural history of Imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. *Am J Surg Pathol* 2011; 35(11):1646-1656
- Da Riva L, Bozzi F, Mondellini P, Miccichè F, Fumagalli E, Vaghi E, Tarantino E, Huber V, **Gronchi A**, Tamborini E, Pierotti MA, Pilotti S and Bongarzone I. Proteomic detection of a large amount of SCGF $\alpha$  in the stroma of GISTs after imatinib therapy. *J Transl Med* 2011; 9:158
- Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer*. 2011; 47(17): 2493-2511
- Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare urogenital cancers in Europe. *Eur J Cancer*. 2012; 48(4):456-464
- Van Dijk BA, Gatta G, Capocaccia R, et al. Rare cancers of the head and neck area in Europe. *Eur J Cancer*. 2012; 48(6):783-796.
- Mallone S, De Vries E, Guzzo M, et al. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. *Eur J Cancer*. 2012; 48(8):1167-1175
- Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, Alberghini M, Mauro V, **Gronchi A**, Dusio GF, Pelosi G, Picci P, Casali PG, Pierotti MA, Pilotti S. Receptor Tyrosine Kinase Pathway Analysis Sheds Light on Similarities between Clear Cell Sarcoma and Metastatic Melanoma. *Gene Chromosomes Cancer* 2012; 51(2): 111-126
- Fiore M, Colombo C; Locati P, Berselli M, Radaelli S, Morosi C, Casali PG and **Gronchi A**. Surgical technique, morbidity and outcome of primary retroperitoneal sarcoma involving inferior vena cava. *Ann Surg Oncol* 2012; 19(2): 511-518.
- Trama A, Mallone S, Nicolai N, Necchi A, Schaapveld M, Gietema J, Znaor A, Ardanaz E, Berrino F; RARECARE Working Group. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. *Eur J Cancer*. 2012; 48(2):159-169
- Faivre J, Trama A, De Angelis R, Elferink M, Siesling S, Audisio R, Bosset JF, Cervantes A, Lepage C; RARECARE Working Group. Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. *Eur J Cancer*. 2012; 48(10):1417-24
- Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, Weber DC, Ricardi U, Slowinski J, Brandes A; RARECARE working group. Epidemiology of glial and non-glial brain tumours in Europe. *Eur J Cancer*. 2012; 48(10):1532-42
- Gatta G, Ferrari A, Stiller CA, Pastore G, Bisogno G, Trama A, Capocaccia R; RARECARE Working Group. Embryonal cancers in Europe. *Eur J Cancer*. 2012; 48(10):1425-33
- van der Zwan JM, Mallone S, van Dijk B, Bielska-Lasota M, Otter R, Foschi R, Baudin E, Links TP; RARECARE WG. Carcinoma of endocrine organs: results of the RARECARE project. *Eur J Cancer*. 2012;48(13):1923-31
- **Gronchi A**, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Perez I, Nieto A, Tercero JC, Alfaro V, Tamborini E and Blay JY. Phase II Clinical Trial of Neoadjuvant Trabectedine in patients with advanced localized myxoid liposarcoma. *Ann Oncol* 2012; 23(3): 771-776

- **Gronchi A**, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG and Picci P. Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas (STS): a Randomized Clinical Trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS). *J Clin Oncol* 2012; 30(8): 350-356
- Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, **Gronchi A**, Amore P, Vinaccia V and Casali PG. A Phase II study on imatinib in advanced chordoma. *J Clin Oncol* 2012; 30(9): 914-920
- **Gronchi A** and Raut CP. The combination of Surgery and Imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. *Ann Surg Oncol* 2012; 19: 1051-1055
- **Gronchi A**, Miceli R, Colombo C, Stacchiotti S, Collini P, Mariani L, Sangalli C, Radaelli S, Sanfilippo R, Fiore M and Casali PG. Frontline extended surgery is associated with improved survival in retroperitoneal low-intermediate grade soft tissue sarcomas. *Ann Oncol* 2012; 23(4):1067-1073
- Siesling S, van der Zwan JM, Izarzugaza I, et al. Rare thoracic cancers, including peritoneum mesothelioma. *Eur J Cancer*. 2012; 48(7):949-960
- Visser O, Trama A, Maynadié M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC; RARECARE Working Group. Incidence, survival and prevalence of myeloid malignancies in Europe. *Eur J Cancer*. 2012; 48(17):3257-66
- Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, **Gronchi A**, Corless CL, Goldstein D, Rubin B, Maki RB, Lazar AJ, Lev D, Trent JC and von Mehren M. Non-random association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): Case series of 28 patients. *Ann Oncol* 2012; 23(5): 1335-1340
- Venturini L, Daidone MG, Motta R, Hoare SF, **Gronchi A**, Folini M, Keith WN, Zaffaroni N. Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. *Neuro-oncology* 2012;14(6):736-744.
- Collini P, Negri T, Barisella M, Stacchiotti S, Palassini E, Tarantino E, Pastorino U, **Gronchi A**, Casali PG and Pilotti S High-Grade sarcomatous overgrowth in Solitary Fibrous Tumors: a clinical-pathological study of 10 cases. *Am J Surg Pathol* 2012; 36(8):1202-1215
- Casali PG, Fumagalli E and **Gronchi A**. Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST). *Curr Treat Opt in Oncol* 2012; 13(3):277-284
- Bonvalot S, Raut CP, Pollock RE, Rutkowski P, Strauss DC, Hayes AJ, Van Coevorden F, Fiore M, Stoeckle E, Hohenberger P and **Gronchi A**. Technical Considerations in Surgery For Retroperitoneal Sarcomas. Position paper from e-SURGE, a masterclass in sarcoma surgery, and EORTC - STBSG. *Ann Surg Oncol* 2012; 19(9):2981–2991
- Colombo C, Ronellenfitch U, Yuxin Z, Rutkowski P, Miceli R, Bylina E, Hohenberger P, Raut CP and **Gronchi A**. Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study. *Ann Surg Oncol* 2012; 19(11):3361-3367
- Reichardt P, Morosi C, Wardelmann E and **Gronchi A**. Gastrointestinal stromal tumors: Evolving role of the multidisciplinary team approach in management. *Expert Rev Anticancer Ther* 2012; 12(8):1053-1068
- Colombo C, R Randall L, Andtbacka RHI and **Gronchi A**. A new surgical perspective in soft tissue sarcoma (STS) management: more conservative in ESTS (Extremity Soft Tissue Sarcoma), more extended in RSTS (Retroperitoneal Soft Tissue Sarcoma). *Expert Rev Anticancer Ther* 2012; 12(8):1079-1087



- Colombo C, Miceli R, Collini P, Radaelli S, Palassini E, Stacchiotti S, Fiore M, Mariani L, Casali PG and **Gronchi A**. Leiomyosarcoma and sarcoma with myogenic differentiation: two different entities or two faces of the same disease? *Cancer* 2012; 118(21): 5349-5357
- Stacchiotti S, Dagrada P, Morosi C, Negri T, Romanini A, Pilotti S, **Gronchi A** and Casali PG. Extraskeletal Myxoid Chondrosarcoma: tumor response to Sunitinib. *Clin Sarcoma Res* 2012; 2(1): 22
- Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Llombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali PG and **Gronchi A**. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy: an exploratory analysis on a Phase III trial. *Cancer* 2012; 118(23):5857-5866
- Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, **Gronchi A**, Dei Tos AP, Morosi C, Messina A, Pilotti S, Casali PG. Sunitinib malate in solitary fibrous tumor (SFT). *Ann Oncol* 2012; 23(12):3171-3179
- **Gronchi A** and Raut CP. Optimal approach to sporadic desmoid tumor: from radical surgery to observation. Time for a consensus ? *Ann Surg Oncol* 2012; 19:3995-3997
- ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7: vii92-99
- ESMO / European Sarcoma Network Working Group. Gastrointestinal Stromal Tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7: vii49-55
- ESMO / European Sarcoma Network Working Group. Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7: vii100-109
- Jakob J, Mussi C, Ronellenfitsch U, Wardelmann E, Negri T, **Gronchi A** and Hohenberger P. Gastrointestinal Stromal Tumor (GIST) of the rectum: results of surgical and multimodality therapy in the era of Imatinib. *Ann Surg Oncol* 2013; 20(2):586-592.
- **Gronchi A**. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with GIST. *Eur J Cancer* 2013; 49: 884-892
- **Gronchi A**, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M and Casali PG. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. *Ann Oncol* 2013; 24(3):817-23
- **Gronchi A**, Miceli R, Shurell E, Eilber FC, Eilber FR, Anaya DA, Kattan MW, Honoré C, Lev DC, Colombo C, Bonvalot S, Mariani L and Pollock RE. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center datasets. *J Clin Oncol* 2013; 31:1649-1655
- Stacchiotti S, Libertini M, Negri T, Palassini E, **Gronchi A**, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S and Casali PG. Response to chemotherapy of Solitary Fibrous Tumor: a retrospective study. *Eur J Cancer* 2013; 49(10): 2376-2383
- **Gronchi A** and Pollock RE. Quality of local treatment or biology of the tumor: which are the trump cards for loco-regional control of retroperitoneal sarcoma? *Ann Surg Oncol* 2013; 20: 2111-2113.
- Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, **Gronchi A**, Pilotti S, Casali PG. Phase II Study on Lapatinib in advanced EGFR positive Chordoma. *Ann Oncol* 2013; 24: 1931–1936

- Rutkowski P and **Gronchi A**. Efficacy and economic value of adjuvant Imatinib in GIST. *The Oncologist* 2013; 18: 689-696.
- Duranti L, **Gronchi A**, Stacchiotti S, Fiore M, Casali PG, Collini P, Pelosi G, Galeone C and Pastorino U. Localized thoracic sarcomas: outcome improvement over time at a single institution. *Eur J Cancer* 2013; 49: 2689-2697
- Baldi G, Stacchiotti S, Mauro V, Dei Tos AP, **Gronchi A**, Pastorino U, Duranti L, Provenzano S, Marrari A, Libertini M, Pilotti S and Casali PG. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. *Clin Sarcoma Res* 2013; 3(1): 4
- Stacchiotti S, Crippa F, Messina A, Pilotti S, **Gronchi A**, Blay JY and Casali PG. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. *Clin Sarcoma Res* 2013; 3(1): 8
- Mattavelli D, Miceli R, Radaelli S, Mattavelli F, Cantù G, Barisella M, Quattrone P, Stacchiotti S, Sangalli C, Casali PG, **Gronchi A** and Fiore M. Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. *Ann Oncol* 2013; 24(8): 2181-2189
- Rutkowski P, **Gronchi A**, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, Fumagalli E, Nyckowski P, Nguyen BP, Kerst JM, Fiore M, Bylina I, Hoiczkyk M, Cats A, Casali PG, Le Cesne A, Treckmann J, Stoeckle E, van de Wilt JH, Sleijfer S, Tielen R, van der Graaf W, Verhoef C and van Coevorden F. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST), the EORTC STBSG experience. *Ann Surg Oncol* 2013; 20(9): 2937-2943
- **Gronchi A** and Casali PG. Adjuvant Therapy for High-Risk Soft Tissue Sarcoma in the Adult. *Curr Treat Opt in Oncol* 2013; 14(3):415-24
- Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, **Gronchi A**, Pilotti S, Zaffaroni N and Casali PG. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-à-vis temozolomide and antiangiogenics. *Clin Cancer Res* 2013; 19(18):5192-201
- **Gronchi A**. Extended surgery for retroperitoneal sarcoma: the key to maximizing the potential for cure and survival. *Pro. Oncology (Williston Park)*. 2013; 27(7):640, 642
- **Gronchi A** and Raut CP. Treatment of localized sarcomas. *Hematol Oncol Clin N Am* 2013; 27:921-938
- Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, Hartgrink HH, Cleton-Jansen AM, Domont J, Bovée JVMG, Bonvalot S, Lev D, and **Gronchi A**. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent multicenter validation study. *Cancer* 2013; 119:3696-3702.
- Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollé J, Sanfilippo R, **Gronchi A**, Perrone F, Tamborini E, Pelosi G, Pierotti M, Maestro R, Priel S and Pilotti S. In vitro and in silico studies of MDM2/MDMX isoforms predict NUTLIN-3A sensitivity in well/differentiated liposarcomas. *Lab Invest* 2013; 93(11): 1232-1240
- Bonvalot S, Ternès N, Fiore M, Bitsakou G, Colombo C, Honoré C, Marrari A, Le Cesne A, Perrone F, Dunant A and **Gronchi A**. Spontaneous regression of primary abdominal wall desmoids: more common than previously thought. *Ann Surg Oncol* 2013; 20(13): 4096-4102
- Raut CP and **Gronchi A**. Cytoreductive Surgery in Advanced GIST: timing is everything. *Ann Surg Oncol* 2013; 20(13): 4059-4060
- Stacchiotti S, Dagrada G, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, **Gronchi A**, Dei Tos AP, Pilotti S and Casali PG. Anthracycline-based CT in extraskelatal myxoid chondrosarcoma: a retrospective study. *Clinical Sarcoma Research* 2013; 3: 16.

- Mallone S, De Angelis R, van der Zwan JM, Trama A, Siesling S, Gatta G, Capocaccia; RARE CARE WG. Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. *Cancer Epidemiol* 2013; 37(6): 850-856
- Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, Casali PG, Fernandez A, Lopez-Pousa A and **Gronchi A**. MRP1 overexpression determines poor prognosis in prospectively treated localized high risk soft tissue sarcoma patients of limbs and trunk wall. An ISG/GEIS study. *Mol Cancer Ther* 2014, 13(1):249-59
- Bozzi F, Manenti G, Conca E, Stacchiotti S, Messina A, Dagrada G, **Gronchi A**, Panizza P, Pierotti M, Tamborini E and Pilotti S. Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. *Neuro-Oncol* 2014; 16(1):72-80
- **Gronchi A**, De Paoli A, Dani C, Merlo DF; Quagliuolo V, Grignani G, Bertola G, Navarra P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorello L, Fiore M, Bruzzi P and Casali PG. Preoperative chemo-radiation therapy for localized retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. *Eur J Cancer* 2014; 50:784-792
- **Gronchi A**, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M and Bonvalot S on behalf of ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm. A position paper from the Italian and the French Sarcoma Group. *Ann Oncol* 2014; 25(3): 578-583
- Meazza C, Luksch R, Daolio P, Podda M, Luzzati A, **Gronchi A**, Parafioriti A, Gandola L, Collini P, Ferrari A, Casanova M, Terenziani M, Spreafico F, Polastri D, Biassoni V, Schiavello E, Pecori E, Massimino M. Axial Skeletal Osteosarcoma: a 25 year monoinstitutional experience in children and adolescence. *Med Onc* 2014; 31(4): 875
- Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczky M, Cats A, Casali PG, Treckmann J, van Coevorden F, **Gronchi A**. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - analysis of prognostic factors (EORTC-STBSG collaborative study). *Eur J Surg Oncol* 2014; 40(4):412-419
- Pastorino U, Duranti L, Scannagatta P, Leo F, Piccioni F, Collini P and **Gronchi A**. Thoracopleuropneumectomy with rib-like reconstruction for recurrent thoracic sarcomas. *Ann Surg Oncol* 2014; 21(5):1610-1615
- Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladdy RA, Casali PG, Swallow CJ, **Gronchi A**, Bonvalot S and Raut RP. Desmoid-type Fibromatosis and pregnancy. A multi-institutional analysis of recurrence and obstetric risk. *Ann Surg* 2014; 259(5):973-978.
- Radaelli S, Stacchiotti S, Casali PG and **Gronchi A**. Emerging Therapies for Adult Soft Tissue Sarcomas. *Exp Rev Anticancer Ther* 2014; 14(6):689-704
- Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, **Gronchi A**, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestri R, Pilotti S and Casali PG. Activity of Sunitinib in Extraskelatal Myxoid Chondrosarcoma. *Eur J Cancer* 2014; 50(9): 1657-1664
- **Gronchi A**, Colombo C and Raut CP. Surgical Management of Localized Soft Tissue Tumors. *Cancer* 2014; 120(17):2638-2648
- De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada GP, Disciglio V, Sanfilippo R, **Gronchi A**, D'Incalci M, Casali PG, Canevari S, Pierotti MA, Pilotti S. Identification of a

gene expression driven progression pathway in Myxoid Liposarcoma. *Oncotarget* 2014; 5(15):5965-5977

- Radaelli S, Desai A, Hodson J, Colombo C, Roberts K, Gourevitch D and **Gronchi A**. Prognostic factors and outcome of Spermatic Cord Sarcoma. *Ann Surg Oncol* 2014; 21:3557-3563
- ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014; 25 (Supplement 3): iii102–iii112.
- ESMO / European Sarcoma Network Working Group. Gastrointestinal Stromal Tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014; 25 (Supplement 3): iii21–iii26.
- ESMO / European Sarcoma Network Working Group. Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014; 25 (Supplement 3): iii113–iii123.
- Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, **Gronchi A**, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JMF and D’Incalci M. Mode of action of trabectedin in myxoid liposarcoma. *Oncogene* 2014; 33(44):5201-5210
- Tazzari M, Negri T, Rini F, Vergani B, Huber V, Villa A, Dagrada P, Colombo C, Fiore M, **Gronchi A**, Stacchiotti S, Casali PG, Pilotti S, Rivoltini L and Castelli C. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. *Br J Cancer* 2014; 11(7):1350-1362
- van Broekhoven DLM, Deroose JP, Bonvalot S, **Gronchi A**, Grünhagen DJ, Eggermont AMM and Verhoef C. Isolated limb perfusion by tumor necrosis factor alpha and melphalan in patients with advanced aggressive fibromatosis. *Br J Surg* 2014; 101(13):1674-80.
- Le Cesne A, Ouali M, Leahy MG, Santoro, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, **Gronchi A**, Hogendoorn PCW, Litiere S, Marreaud S, Blay JY and Van Der Graaf WTA. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. *Ann Oncol* 2014; 25(12):2425-2432
- Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C, Messina A, Dei Tos AP, **Gronchi A** and Casali PG. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. *Clin Sarcoma Res* 2014; 4:16
- Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, **Gronchi A**, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG and Zaffaroni N. Preclinical and clinical evidence of activity of Pazopanib in Solitary Fibrous Tumor. *Eur J Cancer* 2014; 50(17):3021-8
- Morosi C, Stacchiotti S, Marchianò A, Bianchi A, Radaelli S, Sanfilippo R, Colombo C, Richardson C, Collini P, Barisella M, Casali PG, **Gronchi A**, Fiore M. Correlation between Radiological Assessment and Histopathological Diagnosis in Retroperitoneal Tumors: analysis of 291 consecutive patients at a tertiary referral Sarcoma Center. *Eur J Surg Oncol* 2014; 40(12):1662-1670
- Stiller CA, Trama A, Brwster DH, Verne J, Bouchardy C, Navarro C, Chirlaque MD, Marcos-Gragera R, Visser O, Serraino D, Weiderpass E, Dei Tos AP, Ascoli V; Rarecare Working Group. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. *Cancer Epidemiol* 2014; 38(6):670-678

- Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult. A Consensus Approach from the Trans-Atlantic RPS Working group\* *Ann Surg Oncol* 2015; 22(1): 256-263
- Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, Moreau G, Van der Graaf W and **Gronchi A**. Management of Sporadic Desmoid-Type Fibromatosis: A European consensus approach based on patients' and professionals' expertise - A Sarcoma Patients EURONET (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC) / Soft Tissue and Bone Sarcoma Group (STBSG) initiative. *Eur J Cancer* 2015; 51(2):127-136
- Casali PG, Bruzzi P, Bogaerts J and Blay JY on behalf of the Rare Cancers Europe (RCE) Consensus Panel. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. *Ann Oncol* 2015; 26(2):300-306
- Colombo C, Miceli R, Le Péchoux C, Palassini E., Honoré C, Stacchiotti S, Mir O , Casali PG, Dômont J, Fiore M, Le Cesne A, **Gronchi A** and Bonvalot S. Sporadic Extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. *Eur J Cancer* 2015; 51(2):186-192
- Palmerini E, Staals EL, Maki RG, Pengo S, Cioffi A, Gambarotti A, Picci P, Daolio PA, Parafioriti A, Morris C, Antonescu CR, **Gronchi A**, Casali PG, Donati DM, Ferrari S, Stacchiotti S. Tenosynovial giant cell tumor/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. *Eur J Cancer* 2015; 51(2):210-217
- **Gronchi A**. Individualizing the use/non-use of radiation therapy (RT) in soft tissue sarcoma (STS): when abstention is better than care. *J Surg Oncol* 2015; 111(2):133-134
- **Gronchi A**, Collini P, Miceli R, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, Casali PG, Dei Tos AP and Pilotti S. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. *Am J Surg Pathol* 2015; 39(3):383-93
- Stacchiotti S, Sommer J, Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. *Lancet Oncol* 2015;16(2): e71-83
- Colombo C, Baratti D, Kusamura S, Deraco M and **Gronchi A**. The role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Isolated Perfusion (ILP) Interventions in Sarcoma. *J Surg Oncol* 2015; 111(5):570-579
- Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, Casanova J, Esler C, Ferrari S, Funovics PT, Gerrand C, Grimer R, **Gronchi A**, Haffner N, Hecker-Nolting S, Höller S, Jeys L, Jutte P, Leithner A, San-Julian M, Thorkildsen J, Vincenzi B, Windhager R, Whelan J. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study.. *Eur J Cancer* 2015; 51(3):374-81.
- **Gronchi A**, Miceli R, Allard MA, Callegaro D, Le Péchoux C, Fiore M, Honoré C, Sanfilippo R, Coppola S, Stacchiotti S, Terrier P, Casali PG, Le Cesne A, Mariani L, Colombo C and Bonvalot S. Personalizing the approach to Retroperitoneal Soft Tissue Sarcoma: histology specific patterns of failure and post-relapse outcome after primary extended resection. *Ann Surg Oncol* 2015; 22(5):1447-54
- Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litiere S, Bonnetain F, Dabakuyo TS, Benjamin R, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grossclaude P, **Gronchi A**, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Karup-Hansen A, Le Pechoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut CP, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gorgou-Bourgade S, Mathoulin-Pelissier S. Guidelines for time-to-event endpoint definitions in sarcoma and

gastrointestinal stromal tumor (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to event Endpoints in CANcer trials). *Ann Oncol* 2015; 26:865–872

- Callegaro D, Fiore M and **Gronchi A**. Personalizing surgical margins in retroperitoneal sarcoma. *Exp Rev Anticancer Ther* 2015; 15(5):553-67
- Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Mariani L, Amore P, **Gronchi A**, Casali PG, Maestro R, and Dei Tos AP. KIT, PDGFRA and BRAF mutational spectrum impacts on the natural history of Imatinib-naïve localized GIST: a population-based study. *Am J Surg Pathol* 2015; 39(7):922-930
- Callegaro D, Miceli R, Brunelli C, Colombo C, Sanfilippo R, Radaelli S, Casali PG, Caraceni A, **Gronchi A**, Fiore M. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. *Br J Surg* 2015; 102:1079-1087
- Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, **Gronchi A**, Stacchiotti S, Pierotti MA, Negri T and Pilotti S. Solitary Fibrous Tumor: loss of chimeric protein expression and genomic instability mark dedifferentiation. *Mod Pathol* 2015; 28(8):1074-1083
- Hohenberger P, Gorlick R, **Gronchi A**. Collaborations Between SSO and the Connective Tissue Oncology Society (CTOS) Series. *Ann Surg Oncol* 2015; 22(9): 2815-2816
- Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, Comandone A, Sangalli C, Palmerini E, Lopez-Pousa A, De Sanctis R, Bottelli S, Libertini M, Picci P, Casali PG and **Gronchi A**. Feasibility of pre-operative chemotherapy + radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk within the ISG/GEIS randomized clinical trial on 3 vs 5 cycles of full-dose epirubicin + ifosfamide. *J Clin Oncol* 2015; 33(31):3628-3634
- Hindi N, Casali PG, Morosi C, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, **Gronchi A**, Stacchiotti S. Imatinib in advanced chordoma: a retrospective case series analysis. *Eur J Cancer* 2015; 51:2609-14
- Fiore M, Colombo C, Radaelli S, Callegaro D, Palassini E, Barisella M, Morosi C, Baldi GG, Stacchiotti S, Casali PG, **Gronchi A**. Hormonal manipulation with Toremifene in Sporadic Desmoid-type Fibromatosis. *Eur J Cancer* 2015; 51:2800-2807
- Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann J, Goldstein D, Martin Broto J, **Gronchi A**, Dei Tos AP, Matreaud S, van der Graaf W, Zalberg JR, Litiere S and Blay JY. Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with Imatinib as an adjuvant: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS). *J Clin Oncol* 2015; 33:4276-4283
- Wardelmann E, Haas RL, Bovée JVMG, Terrier Ph, Lazar A, Messiou C, LePechoux C, Hartmann W, Collin F, Fisher C, Mechttersheimer G, Dei Tos AP, Stacchiotti S, Jones R, **Gronchi A**, Bonvalot S. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. *Eur J Cancer* 2016; 53:84-95
- Messiou C, Bonvalot S, **Gronchi A**, Vanel D, Meyer M, Robinson P, Morosi C, Bloem JL, Terrier PH, Lazar A, LePechoux C, Wardelman E, Winfield JM, Boulet B, Haas RL. Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological

- examination and reporting with an emphasis on Magnetic Resonance Imaging. *Eur J Cancer* 2016; 56: 37-44
- Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, **Gronchi A**, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG. Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP). *Clin Cancer Res* 2016; 22(4):837-46
  - Vlenterie M, Litière S, Rizzo E, Marréaud S, Judson I, Gelderblom I, Le Cesne A, Wardelmann E, Messiou C, **Gronchi A**, van der Graaf WTA. Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG); Setting a new landmark for studies in this subtype. *Eur J Cancer* 2016; 58: 62-72
  - **Gronchi A**, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE and Raut CP. Variability in patterns of recurrence after resection of Primary Retroperitoneal Sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative Transatlantic RPS Working Group. *Ann Surg* 2016; 263(5):1002-1009
  - Raut CP, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, Fiore M, Callegaro D, Casali PG, Haas RL, Hayes AJ, Honoré C, Cannell AJ, Jakob J, Szacht M, Fairweather M, Pollock RE, Bonvalot S, **Gronchi A**. External Validation of a Multi-Institutional Retroperitoneal Sarcoma Nomogram. *Cancer* 2016; 122(9):1417-24
  - Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Lorusso D, Sabatucci I, Carcangiu ML, Fiore M, **Gronchi A**, Raspagliesi F. Morcellator's port-site metastasis of a uterine smooth muscle tumor of uncertain potential after minimally invasive myomectomy. *J Minim Invasive Gynecol.* 2016; 23(4):647-9.
  - Saponara M, Stacchiotti S and **Gronchi A**. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. *Exp Rev Anticancer Ther* 2016; 16(5):473-484
  - Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pechoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Mariani L, Wunder JS, Pollock RE, Casali PG and **Gronchi A**. Development and external validation of two nomograms to predict overall survival and distant metastases after surgical resection of localised soft tissue sarcomas of the extremities: a retrospective analysis. *Lancet Oncol* 2016; 17:671-680
  - Radaelli S, Fiore M, Colombo C, Ford S, Palassini E, Sanfilippo R, Stacchiotti S, Sangalli C, Morosi C, Casali PG and **Gronchi A**. Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. *Surg Oncol* 2016; 25(3): 125-131
  - **Gronchi A**, Guadagnolo BA, Erinjeri JP. Local Ablative Therapies to Metastatic Soft Tissue Sarcoma. *Am Soc Clin Oncol Educ Book.* 2016;35:e566-e575
  - Radaelli S, Stacchiotti S, Ruggieri P, Donati D, Casali PG, Palmerini E, Collini P, Gambarotti M, Porcu L, Boriani S, **Gronchi A**, Picci P. Sacral Chordoma: Long-Term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. *Spine* 2016; 41(12):1049-1057.
  - Ford S and **Gronchi A**. Indications for Surgery in Advanced/Metastatic GIST. *Eur J Cancer* 2016; 63: 154-167
  - Grünwald V, Young R, Messiou C, Lia M, Wardelmann E, van der Graaf W, **Gronchi A**, Judson I for the EORTC STBSG. Absence of progression, not extent of remission tumour shrinkage defines prognosis in soft tissue sarcoma – an analysis of the EORTC 62012 study of the EORTC STBSG. *Eur J Cancer* 2016; 64:44-51.

- Ray-Coquard I, Litiere S, Rizzo E, Blay JY, Casali PG, Judson I, Krarup Hansen A, Lindner LH, Dei Tos AP, Gelderblom H, Marreaud S, Rutkowski P, Hohenberger P, **Gronchi A**, Van der Graaf WT. Impact of chemotherapy in Uterine Sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other Soft Tissue Sarcoma (STS) patients treated with first line chemotherapy. *Gynecol Oncol* 2016;142(1):95-101
- **Gronchi A**, Haas RL and Bonvalot S. Cancer Registries and randomized clinical trials in rare tumors: at the 2 extremes of daily clinical practice. *Eur J Cancer* 2016; 64:113-115
- Meazza C, Perrone F, Belfiore A, Busico A, Settanni G, Paielli N, Cesana L, Ferrari A, Chiaravalli S, **Gronchi A**, Colombo C, Pilotti S, Massimino A. AKT1 and BRAF mutations in pediatric aggressive fibromatosis. *Cancer Med* 2016; 5(6):1204-13
- Pasquali S, **Gronchi A**, Strauss D, Bonvalot S, Jeys L, Stacchiotti S, Hayes A, Honoré C, Collini P, Renne SL, Alexander N, Grimer RJ, Callegaro D, Sumathi VP, Gourevitch D, Desai A. Resectable extrapleural and extrameningeal Solitary Fibrous Tumor: a multi centre prognostic study. *Eur J Surg Oncol* 2016; 42:1064-1070
- Eastley N, McCulloch T, Esler C, Hennig I, Fairbairn J, **Gronchi A** and Ashford R. Extra-abdominal Desmoids Fibromatosis: a review of management, current guidance and unanswered questions. *Eur J Surg Oncol* 2016; 42:1071-1083
- Stacchiotti A, Provenzano S, Dagrada GP, Negri T, Brich S, Basso U, Brunelio A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, **Gronchi A**, Dei Tos AP, Crippa F, Morosi C, Pilotti S and Casali PG. Sirolimus in advanced hemangioendothelioma: a retrospective case series analysis from the Italian Rare Cancer Network database. *Ann Surg Oncol* 2016; 23(9):2735-44
- van Broekhoven DL, Grünhagenl DJ, van Dalen T, van Coevorden F, Bonenkamp HJ, Been LB, Bemelmans MH, Dijkstra SD, Colombo C, **Gronchi A**, Verhoef C. Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. *BMC Cancer*. 2016;16(1):686
- Fiore M, MacNeill A, **Gronchi A**, Colombo C. Desmoid-type Fibromatosis: evolving treatment standards. *Surg Oncol Clin N Am* 2016; 25:803-826
- Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult. A Consensus Approach from the Trans-Atlantic RPS Working group\*. *Ann Surg Oncol* 2016; 23:3531-3540
- Stacchiotti S, Astolfi A, **Gronchi A**, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, Casali PG, Castelli C, Dagrada GP, Pilotti S, Maestro R. Evolution of Dermatofibrosarcoma protuberans (DFSP) to DFSP-derived fibrosarcoma (FS-DFSP): an event marked by epithelial mesenchymal transition-like process and 22q loss. *Mol Cancer Res* 2016; 14(9):820-9
- **Gronchi A**, Delrio P, Quagliuolo V, Sandrucci S. The Italian Society of Surgical Oncology (SICO) survey on the minimum requirements of rare cancers referral centers. *Updates Surg* in press
- Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, Casali PG, **Gronchi A**, Astolfi A, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C. Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment. *J Invest Dermatol* in press
- Gasparotto D, Rossi S, Polano M, Tamborini E, Lorenzetto E, Sbaraglia M, Mondello A, Massani M, Lamon S, Bracci R, Mandolesi A, Frate E, Stanzial F, Agaj J, Mazzoleni G, **Gronchi A**, Dei Tos AP and Maestro R. Quadruple-negative GIST is a sentinel for unrecognized Neurofibromatosis Type 1 syndrome. *Clin Cancer Res* in press



- Sandrucci S, Trama A, Quagliuolo V, **Gronchi A**. Accreditation for centers of sarcoma surgery. Updates Surg in press
- **Gronchi A**, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch S, Dei Tos AP, Collini P, Cruz Jurado J, De Paoli A, Donati DM, Poveda A, Quagliuolo A, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG and Picci P. Short, Full-Dose Adjuvant Chemotherapy (CT) in High-Risk Adult Soft Tissue Sarcomas (STS): Long term Follow-Up of a Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. Ann Oncol in press
- Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Boccone P, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf W, Touati N, Litière S, Marreaud S, **Gronchi A**, Kasper B. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol in press
- Tseng WW, Pollock RE and **Gronchi A**. The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG): “Red wine or white”? Ann Surg Oncol in press
- Saponara M, Stacchiotti S, Casali PG and **Gronchi A**. (Neo)adjuvant treatment in localized soft tissue sarcoma (STS): the unsolved affair. Eur J Cancer in press